STOCK TITAN

SURGERY PARTNERS, INC. and Bain Capital Conclude Discussions

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Surgery Partners (NASDAQ:SGRY) announced that discussions with Bain Capital regarding their proposal to acquire remaining outstanding shares have concluded without a deal. The Independent Committee determined that the company's prospects as a public entity exceeded Bain's proposal value. Surgery Partners reaffirmed its 2025 financial guidance, projecting revenues of $3.30-3.45 billion and Adjusted EBITDA of $555-565 million. The company plans to host an Investor Day in H2 2025 to present its growth strategy. Management expressed confidence in the company's positioning in the outpatient surgical care market, citing strong Q1 performance, favorable surgical trends, and a positive regulatory landscape. Bain Capital, while unable to reach agreement terms, remains optimistic about Surgery Partners' business and will continue as long-term investors.
Surgery Partners (NASDAQ:SGRY) ha annunciato che le trattative con Bain Capital riguardo alla proposta di acquisire le azioni residue in circolazione si sono concluse senza un accordo. Il Comitato Indipendente ha stabilito che le prospettive dell'azienda come società quotata superano il valore proposto da Bain. Surgery Partners ha confermato le previsioni finanziarie per il 2025, prevedendo ricavi tra 3,30 e 3,45 miliardi di dollari e un EBITDA rettificato tra 555 e 565 milioni di dollari. La società prevede di organizzare un Investor Day nella seconda metà del 2025 per illustrare la propria strategia di crescita. Il management ha espresso fiducia nella posizione dell'azienda nel mercato della chirurgia ambulatoriale, citando una forte performance nel primo trimestre, tendenze chirurgiche favorevoli e un contesto normativo positivo. Bain Capital, pur non avendo raggiunto un accordo, rimane ottimista sul business di Surgery Partners e continuerà a essere un investitore a lungo termine.
Surgery Partners (NASDAQ:SGRY) anunció que las negociaciones con Bain Capital sobre su propuesta para adquirir las acciones pendientes restantes concluyeron sin un acuerdo. El Comité Independiente determinó que las perspectivas de la empresa como entidad pública superan el valor propuesto por Bain. Surgery Partners reafirmó sus previsiones financieras para 2025, proyectando ingresos de 3,30 a 3,45 mil millones de dólares y un EBITDA ajustado de 555 a 565 millones de dólares. La compañía planea realizar un Día del Inversor en la segunda mitad de 2025 para presentar su estrategia de crecimiento. La dirección expresó confianza en la posición de la empresa en el mercado de atención quirúrgica ambulatoria, destacando un sólido desempeño en el primer trimestre, tendencias quirúrgicas favorables y un entorno regulatorio positivo. Bain Capital, aunque no logró llegar a un acuerdo, sigue siendo optimista sobre el negocio de Surgery Partners y continuará como inversor a largo plazo.
Surgery Partners(NASDAQ:SGRY)는 남은 주식 인수를 위한 Bain Capital과의 논의가 합의 없이 종료되었음을 발표했습니다. 독립 위원회는 회사가 상장 기업으로서의 전망이 Bain의 제안 가치를 초과한다고 판단했습니다. Surgery Partners는 2025년 재무 지침을 재확인하며, 매출 33억~34.5억 달러와 조정 EBITDA 5억 5,500만~5억 6,500만 달러를 예상하고 있습니다. 회사는 2025년 하반기에 투자자 설명회를 개최해 성장 전략을 발표할 계획입니다. 경영진은 1분기 강력한 실적, 긍정적인 수술 트렌드, 우호적인 규제 환경을 근거로 외래 수술 시장에서 회사의 입지에 자신감을 표명했습니다. Bain Capital은 합의에 이르지 못했지만 Surgery Partners 사업에 대해 낙관적이며 장기 투자자로 남을 것이라고 밝혔습니다.
Surgery Partners (NASDAQ:SGRY) a annoncé que les discussions avec Bain Capital concernant leur proposition d'acquérir les actions restantes en circulation se sont conclues sans accord. Le Comité Indépendant a déterminé que les perspectives de la société en tant qu'entité publique dépassaient la valeur proposée par Bain. Surgery Partners a réaffirmé ses prévisions financières pour 2025, anticipant un chiffre d'affaires de 3,30 à 3,45 milliards de dollars et un EBITDA ajusté de 555 à 565 millions de dollars. La société prévoit d'organiser une Journée des Investisseurs au second semestre 2025 pour présenter sa stratégie de croissance. La direction a exprimé sa confiance dans la position de l'entreprise sur le marché des soins chirurgicaux ambulatoires, citant une solide performance au premier trimestre, des tendances chirurgicales favorables et un environnement réglementaire positif. Bain Capital, bien qu'incapable de conclure un accord, reste optimiste quant à l'activité de Surgery Partners et continuera d'être un investisseur à long terme.
Surgery Partners (NASDAQ:SGRY) gab bekannt, dass die Gespräche mit Bain Capital über deren Angebot zum Erwerb der restlichen ausstehenden Aktien ohne Einigung beendet wurden. Das unabhängige Komitee stellte fest, dass die Aussichten des Unternehmens als börsennotierte Gesellschaft den Wert des Bain-Angebots übersteigen. Surgery Partners bestätigte seine Finanzprognosen für 2025 und erwartet Umsätze zwischen 3,30 und 3,45 Milliarden US-Dollar sowie ein bereinigtes EBITDA von 555 bis 565 Millionen US-Dollar. Das Unternehmen plant, im zweiten Halbjahr 2025 einen Investorentag abzuhalten, um seine Wachstumsstrategie vorzustellen. Das Management zeigte sich zuversichtlich bezüglich der Positionierung des Unternehmens im ambulanten chirurgischen Versorgungsmarkt und verwies auf eine starke Performance im ersten Quartal, positive chirurgische Trends und ein günstiges regulatorisches Umfeld. Bain Capital bleibt trotz des fehlenden Einigungsergebnisses optimistisch hinsichtlich des Geschäfts von Surgery Partners und wird als langfristiger Investor weiterhin engagiert bleiben.
Positive
  • Strong Q1 2025 performance reinforcing company's growth trajectory
  • Reaffirmed robust 2025 guidance: $3.30-3.45B revenue and $555-565M Adjusted EBITDA
  • Independent Committee's confidence in company's long-term value creation potential
  • Continued support from major investor Bain Capital despite failed acquisition talks
  • Strong positioning in high-growth outpatient surgical care market
Negative
  • Failed acquisition talks with Bain Capital could impact short-term stock performance
  • Potential missed opportunity for immediate shareholder value through acquisition premium

Insights

Bain Capital's failed acquisition attempt signals Surgery Partners' confidence in standalone growth prospects exceeding buyout valuation.

The termination of acquisition discussions between Surgery Partners and Bain Capital represents a pivotal moment for the company's trajectory. The Independent Committee's rejection of Bain's proposal indicates they believe the company's intrinsic value exceeds what Bain was willing to pay - a strong vote of confidence in Surgery Partners' standalone growth potential.

Analyzing the dynamics, this outcome suggests two important realities: first, Bain Capital (already a significant investor) couldn't justify a premium that satisfied independent directors, and second, the board sees greater long-term value creation through continued execution of their current strategy rather than through an immediate premium sale.

The announcement of an upcoming Investor Day in H2 2025 isn't coincidental - it's a strategic move to articulate their value creation path to potentially skeptical shareholders who might have preferred the immediate liquidity of a buyout. The reaffirmation of 2025 guidance ($3.30-3.45 billion revenue and $555-565 million Adjusted EBITDA) serves as a concrete commitment to near-term execution.

What's particularly telling is that Bain Capital, despite the failed acquisition, expressed they remain "tremendously optimistic" about Surgery Partners' prospects. This suggests the disagreement was primarily over valuation rather than strategic direction, implying both parties see substantial upside in the outpatient surgical facility market but differed on how to value it.

The board's confidence appears grounded in several factors: their joint venture model, M&A capabilities, and demographic/policy tailwinds in the outpatient surgical space. The decision effectively places the burden on management to deliver the growth algorithm they've promised - making execution over the coming quarters critically important to validate this decision.

--

Board reaffirms its confidence in the Company’s long-term growth prospects; Company reiterates full-year 2025 financial guidance

Company expects to host an Investor Day in the second half of 2025 to discuss its future growth plans and long-term outlook
--

BRENTWOOD, Tenn., June 17, 2025 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or the “Company”), a leading short-stay surgical facility owner and operator, today announced that a Special Committee of independent directors of the Board (the “Independent Committee”) and Bain Capital Private Equity, LP (“Bain Capital”) have concluded discussions related to Bain Capital’s non-binding proposal to acquire all the outstanding shares of Surgery Partners not already owned by Bain Capital (the “Proposal”).

The Independent Committee, after considering the Proposal and with the assistance of independent financial and legal advisors, ultimately determined that Surgery Partners’ prospects to deliver long-term growth and value creation as an independent publicly traded company exceeded the value of the Proposal. The Independent Committee’s conclusion demonstrates its ongoing confidence in the Company’s ability to continue implementing its established long-term growth algorithm and disciplined business execution to enhance shareholder value.

Brent Turner, Chairman of the Independent Committee, commented, “Surgery Partners offers a unique, scaled platform in the high-growth outpatient surgical care market that leverages its proven joint venture model, strong M&A track record, and favorable demographic and policy tailwinds. Following review of the Proposal and discussions with Bain Capital, the Independent Committee concluded that the best path forward for Surgery Partners and its stockholders is to continue operating as an independent publicly traded company. We remain confident in the management team’s ability to continue delivering sustained growth and significant stockholder returns.”

“Our strong first quarter performance gives us even more confidence in our ability to achieve our full-year 2025 revenue and Adjusted EBITDA guidance, reinforcing that Surgery Partners is well positioned to deliver results that support our long-term growth algorithm,” said Eric Evans, CEO of Surgery Partners. “Given favorable surgical trends and our bullish outlook on the regulatory landscape, we continue to be excited by Surgery Partners’ unique competitive positioning and growth potential. As we focus on building upon our strong track record of industry-leading earnings growth and consistent execution, we look forward to continuing our productive relationship with Bain Capital as we pursue our shared goal of delivering long-term value.”

“While we were not able to agree to terms of a transaction, we remain tremendously optimistic about the business, leadership team, and growth strategy of Surgery Partners. We look forward to continuing to work with Surgery Partners as long-term investors and collaborators,” said Bain Capital Partners Andrew Kaplan and Devin O’Reilly.

Surgery Partners expects to host an Investor Day in the second half of 2025, during which the Company plans to present its go-forward strategy for the business, provide an outlook on key industry trends, and detail its plans to maximize portfolio performance, advance its M&A pipeline, and drive operational efficiencies.

2025 Outlook

The Company reaffirmed its outlook for 2025 revenues and Adjusted EBITDA to be in the range of $3.30 billion to $3.45 billion, and $555 million to $565 million, respectively.

About Surgery Partners

Headquartered in Brentwood, Tennessee, Surgery Partners is a leading healthcare services company with a differentiated outpatient delivery model focused on providing high-quality, cost-effective solutions for surgical and related ancillary care in support of both patients and physicians. Founded in 2004, Surgery Partners is one of the largest and fastest growing surgical services businesses in the country, with more than 200 locations in 30 states, including ambulatory surgery centers, surgical hospitals, multi-specialty physician practices and urgent care facilities. For additional information, visit www.surgerypartners.com.

Forward-Looking Statements

This press release contains forward-looking statements, including those regarding growth, our 2025 outlook and our ability to achieve it, our ability to continue delivering sustained double-digit earnings growth, our plans for an Investor Day, our relationship with Bain Capital and other similar statements. These statements can be identified by the use of words such as "believes," "anticipates," "expects," "intends," "plans," "continues," "estimates," "predicts," "projects," "forecasts," "may," "could," and similar expressions. All forward-looking statements are based on current expectations and beliefs as of the date of this release and are subject to risks, uncertainties and other factors that may cause actual results to differ materially from the expectations discussed in, or implied by, the forward-looking statements. Many of these factors are beyond our ability to control or predict including, without limitation, reductions in payments from government health care programs and private insurance payors, such as health maintenance organizations, preferred provider organizations, and other managed care organizations and employers; our ability to contract with private insurance payors; changes in our payor mix or surgical case mix; failure to maintain or develop relationships with physicians on beneficial or favorable terms, or at all; the impact of payor controls designed to reduce the number of surgical procedures; our efforts to integrate operations of acquired or developed businesses and surgical facilities, attract new physician partners, or acquire additional surgical facilities; supply chain issues, including shortages or quality control issues with surgery-related products, equipment and medical supplies; competition for physicians, nurses, strategic relationships, acquisitions and managed care contracts; our ability to attract and retain qualified health care professionals; our ability to enforce non-compete restrictions against our physicians; our ability to manage material liabilities whether known or unknown incurred as a result of acquiring or operating surgical facilities; the impact of future legislation and other health care regulatory reform actions, and the effect of that legislation and other regulatory actions on our business; our ability to comply with current health care laws and regulations; the outcome of legal and regulatory proceedings that have been or may be brought against us; the impact of cybersecurity attacks or intrusions, changes in the regulatory, economic and other conditions of the states where our surgical facilities are located; our indebtedness; the social and economic impact of a pandemic, epidemic or outbreak of a contagious disease on our business; disruptions from weather events and other natural disasters, including hurricanes and the risks and uncertainties identified and discussed from time to time in the Company’s reports filed with the SEC, including in Item 1A under the heading "Risk Factors" in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 and other reports filed with the SEC. Except as required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements to reflect events or circumstances after the date of this report, or to reflect the occurrence of unanticipated events or circumstances.

Investor Relations Contact

(615) 234-8940
IR@surgerypartners.com

Media Contact

press@surgerypartners.com


FAQ

Why did Surgery Partners (SGRY) reject Bain Capital's acquisition proposal?

The Independent Committee determined that Surgery Partners' prospects for long-term growth and value creation as an independent public company exceeded the value of Bain Capital's proposal.

What is Surgery Partners' (SGRY) revenue guidance for 2025?

Surgery Partners reaffirmed its 2025 revenue guidance of $3.30-3.45 billion and Adjusted EBITDA guidance of $555-565 million.

Will Bain Capital remain invested in Surgery Partners (SGRY)?

Yes, Bain Capital stated they will continue as long-term investors and collaborators with Surgery Partners despite the failed acquisition talks.

When is Surgery Partners (SGRY) hosting its Investor Day?

Surgery Partners plans to host an Investor Day in the second half of 2025 to present its growth strategy and industry outlook.

What are the key growth drivers for Surgery Partners (SGRY)?

The company cites its joint venture model, strong M&A track record, favorable demographics, policy tailwinds, and positioning in the outpatient surgical care market as key growth drivers.
Surgery Partners Inc

NASDAQ:SGRY

SGRY Rankings

SGRY Latest News

SGRY Stock Data

2.97B
76.28M
1.47%
113.34%
7.82%
Medical Care Facilities
Services-general Medical & Surgical Hospitals, Nec
Link
United States
BRENTWOOD